The disclosure relates to nucleic acids having Apoptotic Sequence Nos. 5,
8, 9, 11, 14, 60 and 66. It also relates to agents targeting Apoptotic
Sequences, said agents having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7. The composition may
also include a pharmaceutically acceptable carrier. The disclosure also
includes a method of killing a cancer cell by administering to a cancer
cell a treatment formulation including a nucleic acid having an Apoptotic
Sequence targeting agent of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7 and a
pharmaceutically acceptable carrier. The cancer cell may be located in a
subject with cancer.